Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Diabetes Class Warning For Abilify Cites “Paucity” Of Reports

Executive Summary

Bristol-Myers Squibb's Abilify now carries a diabetes class warning for atypical antipsychotics, although the company plans to continue discussions with FDA about modifications as new data become available

You may also be interested in...



Texas Medicaid Restricts Zyprexa Use; Effect To Stabilize Soon, Lilly Says

The impact of Texas Medicaid's decision to require prior authorization for Zyprexa will stabilize after about six months, Lilly Investor Relations Manager Heidi Straub said April 19

Texas Medicaid Restricts Zyprexa Use; Effect To Stabilize Soon, Lilly Says

The impact of Texas Medicaid's decision to require prior authorization for Zyprexa will stabilize after about six months, Lilly Investor Relations Manager Heidi Straub said April 19

Abilify “Dear Doctor” letter

Bristol-Myers Squibb's March 25 "Dear Doctor" 1letter on the atypical antipsychotic class warning for diabetes says "an exhaustive review of the Abilify database revealed no increased signal for diabetes," although "additional information is needed to confirm this." Bristol and Otsuka updated Abilify (aripiprazole) labeling in March to reflect FDA's requested class warning (2"The Pink Sheet" April 5, 2004, p. 32)...

Related Content

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel